N-acetyl-cysteine (NAC)
90 enteric coated capsules

N-acetyl-cysteine (NAC) is a specially modified form of the dietary amino acid cysteine. When taken orally, NAC helps make glutathione, one of the body’s most important antioxidant enzymes. In fact, a number of human and animal studies of NAC have shown it to be a powerful antioxidant.

By displacing homocysteine from its protein binding site, and thereby increasing its metabolism, NAC can be used as an adjunct in helping to reduce homocysteine levels, which is important for heart health.*

Several European studies from the 1980’s provided evidence that NAC is clinically proven to support lung and bronchial health.* It is believed that NAC supports immune system function through its effects on the production and release of cytokines.


*These statements have not been evaluated by the Food and Drug Administration.This product is not intended to diagnose, treat, cure, or prevent any disease.

Supplement Facts

Serving Size 1 enteric coated capsule

Amount Per Serving
N-acetyl-cysteine (NAC).....................600 mg

OTHER INGREDIENTS: Rice Flour Powder, Gelatin, Silicon Dioxide, Magnesium Stearate, Methacrylic Triacetin, FCC; Vanilla Flavor.

This product contains NO milk, egg, fish, peanuts, crustacean shellfish, soybeans, tree nuts, wheat, yeast, or gluten.

Contains NO sugar, and no artificial sweeteners, flavors, colors, or preservatives.

Although manufacturing equipment is thoroughly cleansed after all production runs, this product is manufactured in a facility that utilizes milk, egg, fish, peanuts, crustacean shellfish, soybeans, tree nuts, wheat, yeast, and gluten.

Directions: Take one (1) enteric coated capsule daily with or without food, or as directed by your physician.

*These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure, or prevent any disease.

References

Bridgeman MM, Marsden M, MacNee W, et al. Cysteine and glutathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with N-acetylcysteine. Thorax. 1991 Jan;46(1):39-42.

Raijmakers MT, Schilders GW, Roes EM, et al. N-Acetylcysteine improves the disturbed thiol redox balance after methionine loading. Clin Sci (Lond). 2003 Aug;105(2):173-80.

Roes EM, Raijmakers MT, Peters WH, et al. Effects of oral N-acetylcysteine on plasma homocysteine and whole blood glutathione levels in healthy, non-pregnant women. Clin Chem Lab Med. 2002 May;40(5):496-8.

Wiklund O, Fager G, Andersson A, et al. N-acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein(a) levels. Atherosclerosis. 1996 Jan 5;119(1):99-106.

Hultberg B, Andersson A, Masson P, et al. Plasma homocysteine and thiol compound fractions after oral administration of N-acetylcysteine. Scand J Clin Lab Invest. 1994 Oct;54(6):417-22.

Grandjean EM, Berthet P, Ruffmann R, et al. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther. 2000;22:209-221.

Riise GC, Larsson S, Larsson P, et al. The intrabronchial microbial flora in chronic bronchitis patients: a target for N-acetylcysteine therapy? Eur Respir J. 1994;7:94-101.

Rasmussen JB, Glennow C. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis. Eur Respir J. 1988;1:351-355.

Parr GD, Huitson A. Oral Fabrol (oral N-acetyl-cysteine) in chronic bronchitis. Br J Dis Chest. 1987 Oct;81(4):341-8.

[No authors listed] Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. British Thoracic Society Research Committee. Thorax. 1985 Nov;40(11):832-5.

Grassi C, Morandini GC. A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis. Eur J Clin Pharmacol. 1976;9:393-396.

Boman G, Bcker U, Larsson S, et al. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis. 1983;64:405-415.

De Flora S, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J. 1997 Jul;10(7):1535-41.

Peristeris P, Clark BD, Gatti S, et al. N-acetylcysteine and glutathione as inhibitors of tumor necrosis factor production. Cell Immunol. 1992 Apr;140(2):390-9.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Click label to view larger.